A nurse prepares a shot of the Pfizer-BioNTech COVID-19 vaccine at Guy's Hospital in London, Tuesday, Dec. 8, 2020, as the U.K. health authorities rolled out a national mass vaccination program. U.K. regulators said Wednesday Dec. 9, 2020, that people who have a “significant history’’ of allergic reactions shouldn’t receive the new Pfizer/BioNTech vaccine while they investigate two adverse reactions that occurred on the first day of the country’s mass vaccination program. (AP Photo/Frank Augstein, Pool)

US panel endorses widespread use of Pfizer COVID-19 vaccine

WASHINGTON — A U.S. government advisory panel endorsed widespread use of Pfizer’s coronavirus vaccine Thursday, putting the country just one step away from launching an epic vaccination campaign against the outbreak that has killed close to 300,000 Americans.

Shots could begin within days, depending on how quickly the Food and Drug Administration signs off, as expected, on the expert committee’s recommendation.

“This is a light at the end of the long tunnel of this pandemic,” declared Dr. Sally Goza, president of the American Academy of Pediatrics.

In a 17-4 vote with one abstention, the government advisers concluded that the vaccine from Pfizer and its German partner BioNTech appears safe and effective for emergency use in adults and teenagers 16 and over.

That endorsement came despite questions about allergic reactions in two people who received the vaccine earlier this week when Britain became the first country to begin dispensing the Pfizer-BioNTech shot.

While there are a number of remaining unknowns about the vaccine, in an emergency, “the question is whether you know enough” to press ahead, said panel member Dr. Paul Offit of Children’s Hospital of Philadelphia. He concluded that the potential benefits outweigh the risks.

The decision came as COVID-19 cases surge to ever-higher levels across the U.S., with deaths setting an all-time, one-day record of more than 3,100 on Wednesday.

Pfizer has said it will have about 25 million doses of the two-shot vaccine for the U.S. by the end of December. But the initial supplies will be reserved primarily for health care workers and nursing home residents, with other vulnerable groups next in line until ramped-up production enables shots to become widely available on demand — something that will probably not happen until the spring.

Next week, the FDA will review a second vaccine, from Moderna and the National Institutes of Health, that appears about as protective as Pfizer-BioNTech’s shot. A third candidate, from Johnson & Johnson, which would require just one dose, is working its way through the pipeline. Behind that is a candidate from AstraZeneca and Oxford University.

U.S. health experts are hoping a combination of vaccines will ultimately enable the U.S. to conquer the outbreak.

Still, experts estimate at least 70% of the U.S. population will have to be vaccinated to achieve herd immunity, the point at which the virus can be held in check. That means it could be several months before things start get back to normal and Americans can put away their masks.

All eyes now turn to the FDA staff scientists who will make the final decision of whether to press ahead with large-scale immunizations with Pfizer-BioNTech’s vaccine. FDA’s vaccine director Dr. Peter Marks said a decision would come within “days to a week.”

Dr. William Moss of Johns Hopkins University, who was not involved in the expert panel’s review, welcomed the outcome, saying, “Given how bad the pandemic is now, we need to move.”

The independent review by non-government experts in vaccine development, infectious diseases and medical statistics was considered critical to boosting Americans’ confidence in the safety of the shot, which was developed at breakneck speed less than a year after the virus was identified.

Regulators not only in Britain but in Canada have already approved the vaccine for use in their countries, and President Donald Trump and White House officials have complained for weeks that the FDA was moving too slowly.

“Americans want us to do a scientific review, but I think they also want us to make sure we’re not wasting time on paperwork as opposed to going forward with the decision,” FDA Commissioner Stephen Hahn said before the meeting.

FDA scientists issued a glowing review of the vaccine earlier in the week. Agency staffers said data from Pfizer’s ongoing study of 44,000 people showed strong protection across different age groups, races and health conditions with no major, unexpected safety problems.

The Pfizer-BioNTech shot remains experimental because that final-stage study isn’t complete. As a result, the expert panel wrestled with a list of questions that have yet to be answered.

For example, while the vaccine is more than 90% effective in blocking the symptoms of COVID-19, the FDA’s advisers stressed it is not yet clear whether it can stop the silent, symptomless spread that accounts for up to half of all cases.

“Even though the individual efficacy of this vaccine is very, very, very high, you really as of right now do not have any evidence” that it will lower transmission, said Dr. Patrick Moore of the University of Pittsburgh. He urged Pfizer to take additional steps to answer that question.

Members worried, too, that Pfizer will lose its opportunity to answer critical questions once it begins offering the real vaccine to study participants who had been getting dummy shots up to now.

The company proposed gradually moving those patients to the vaccine group, with priority based on age, health conditions and other factors. Under that plan, 70-year-old participants would cross over before healthy 30-year-olds.

Pfizer must still show whether the vaccine works in children younger than 16 and in pregnant women.

On the safety front, as widespread vaccinations begin, the first recipients will be closely tracked by government health authorities, since studies in tens of thousands of people can’t detect side effects that strike 1 in a million.

Hanging over the meeting were the British allergic reactions and a warning from authorities there that people with a history of serious reactions shouldn’t get the vaccine for now.

Pfizer representatives said they have seen no signs of allergic reactions in their trial. But some of the FDA advisers fear the British warning will deter millions of Americans with allergies who might benefit from the COVID-19 vaccine from giving it a try, and urged additional studies to try to settle the issue.

“This issue is not going to die until we have better data,” Offit said.

Get local stories you won't find anywhere else right to your inbox.
Sign up here

 

A pharmacist passes syringes from a clean room into the main pharmacy, Wednesday, Dec. 9, 2020 at Mount Sinai Queens hospital in New York. The hospital expects to receive thousands of doses once a COVID-19 vaccine is approved. (AP Photo/Mark Lennihan)

Documents created by the Food and Drug Administration for the meeting with the FDA advisory panel, as Pfizer seeks approval for emergency use of their COVID-19 vaccine, are seen on Thursday, Dec. 10, 2020. The FDA panel functions like a science court. During the scheduled daylong session, it was expected to debate and pick apart the data on whether the vaccine is safe and effective enough to be cleared for emergency use. (AP Photo/Jon Elswick)

Just Posted

City of Red Deer says its roundabouts have sharply reduced the number of injury collisions at a pair of busy intersections. Alberta Transportation wants to incorporate five roundabouts into plans to twin Highway 11 from Sylvan Lake to Rocky Mountain House. Photo by PAUL COWLEY/Advocate staff
Highway 11 roundabouts will increase safety based on Red Deer’s experience

Injury collisions sharply reduced at roundabout intersections in city

As of Friday, Alberta has under 10,000 active COVID-19 cases. (Image courtesy CDC)
One new COVID-19 death in Red Deer, Alberta under 10,000 active cases

Alberta reported an additional 643 COVID-19 cases Friday. The province now has… Continue reading

About 110 students from Red Deer Catholic Regional Schools participated in March for Life rally in Edmonton May 9. (File photo by Advocate staff)
Red Deer high school has COVID-19 case

St. Joseph High School in Red Deer confirmed a positive COVID-19 case… Continue reading

Lacombe High School logo.
Two more COVID-19 cases at Lacombe Composite High School

Lacombe Composite High School confirmed two more positive COVID-19 cases at the… Continue reading

World Juniors’ referee Mike Langin makes a called during the Canada vs. Slovakia at the 2021 World Junior Championship at Rogers Place in Edmonton, Dec. 27, 2020. (Photo by Matthew Murnaghan/Hockey Canada)
Former Sylvan Lake man lives his dream at World Junior Championships

Mike Langin was one the 25 Canadian officials who worked during the tournament

Former Alberta Premier Rachel Notley shakes hands with Joel Ward, former Red Deer College President and CEO, as Notley announces that the college is on the path to grant degrees. Red Deer-South MLA Jason Stephan says university status is not a necessary condition for offering degrees. (File photo by Advocate staff)
Future of Red Deer University increasingly uncertain

MLA’s college update says RDC more like SAIT and NAIT than a university

There are two confirmed COVID-19 cases at Red Deer College. Photo by Mamta Lulla/Advocate staff
Central Albertans were promised a university

Central Albertans were promised a university

FILE - Baseball Hall of Famer Hank Aaron sits for a portrait after receiving his COVID-19 vaccination at the Morehouse School of Medicine in Atlanta, in this Tuesday, Jan. 5, 2021, file photo. Hank Aaron, who endured racist threats with stoic dignity during his pursuit of Babe Ruth but went on to break the career home run record in the pre-steroids era, died early Friday, Jan. 22, 2021. He was 86. The Atlanta Braves said Aaron died peacefully in his sleep. No cause of death was given. (AP Photo/Ron Harris, File)
Hank Aaron, baseball’s one-time home run king, dies at 86

Hank Aaron, baseball’s one-time home run king, dies at 86

Miami Heat guard Duncan Robinson (55) passes the ball around Toronto Raptors guard Fred VanVleet (23) during the second half of an NBA basketball game Friday, Jan. 22, 2021, in Tampa, Fla. (AP Photo/Chris O'Meara)
Powell, Raptors regroup after blowing lead, beat Heat 101-81

Powell, Raptors regroup after blowing lead, beat Heat 101-81

Tavares scores winner on power play, Leafs beat Oilers 4-2

Tavares scores winner on power play, Leafs beat Oilers 4-2

David Shoemaker, chief executive officer of the Canadian Olympic Committee, speaks during the Olympic Partnership kick off event at the Sobey's office in Mississauga, Ont. on Monday, October 7, 2019. Shoemaker says the IOC remains committed to staging the Summer Games in Tokyo this summer.THE CANADIAN PRESS/ Tijana Martin
Canada’s Olympic athletes try to tune out reports six months from Games

Canada’s Olympic athletes try to tune out reports six months from Games

Toronto FC captain Michael Bradley lifts the Voyageurs Cup after beating Vancouver Whitecaps 5-2 to win the Canadian Championship Final in Toronto on Wednesday, August 15, 2018. THE CANADIAN PRESS/Chris Young
Forge FC-Toronto FC Canadian Championship final to be played before April 6

Forge FC-Toronto FC Canadian Championship final to be played before April 6

Canada's Penny Oleksiak reacts after her heat of the women's 50m butterfly at the World Swimming Championships in Gwangju, South Korea, Friday, July 26, 2019. THE CANADIAN PRESS/AP-Lee Jin-man
Penny Oleksiak, Kylie Masse among six swimmers named early to Canadian Olympic team

Penny Oleksiak, Kylie Masse among six swimmers named early to Canadian Olympic team

Ontario skip Glenn Howard watches a rock as they play Newfoundland and Labrador in draw 15 action at the Tim Hortons Brier curling championship at Mile One Centre in St. John's on Thursday, March 9, 2017. Curling Canada has decided to use the national ranking system as its selection criteria for the final wild-card berths at the Scotties Tournament of Hearts and Tim Hortons Brier.THE CANADIAN PRESS/Andrew Vaughan
Canadian rankings to be used to determine final wild-card spots at Scotties and Brier

Canadian rankings to be used to determine final wild-card spots at Scotties and Brier

Most Read